AR054090A1 - Derivados de quinuclidina como antagonistas del receptor muscarinico m3. composiciones farmaceuticas y proceso de obtencion - Google Patents
Derivados de quinuclidina como antagonistas del receptor muscarinico m3. composiciones farmaceuticas y proceso de obtencionInfo
- Publication number
- AR054090A1 AR054090A1 ARP050104547A ARP050104547A AR054090A1 AR 054090 A1 AR054090 A1 AR 054090A1 AR P050104547 A ARP050104547 A AR P050104547A AR P050104547 A ARP050104547 A AR P050104547A AR 054090 A1 AR054090 A1 AR 054090A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydroxy
- hydrogen
- alkoxy
- positions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describen composiciones farmacéuticas que contienen a los compuestos, y un proceso para la preparacion de los compuestos. Reivindicacion 1: Un compuesto de la formula (1), en forma de sal o zwiterionica, en donde: R1 y R2 son cada uno independientemente fenilo, estando uno o ambos de R1 y R2 sustituido en una, dos, o tres posiciones por halogeno, alquilo C1-8, o alcoxilo C1-8, y R3 es hidrogeno, hidroxilo, alquilo C1-8, alcoxilo C1-8, o tioalquilo C1-8; o R1 y R2 son cada uno fenilo insustituidos, y R3 es hidrogeno, alquilo C1-8, alcoxilo C1-8, o tioalquilo C1-8; o R1 es cicloalquilo C3-8. o un grupo heterocíclico de 4 a 6 miembros que contiene cuando menos un heteroátomo del anillo seleccionado a partir de nitrogeno, oxígeno, y azufre; R2 es fenilo opcionalmente sustituido en una, dos, o tres posiciones por halogeno, alquilo C1-8, o alcoxilo C1-8; o R2 es un grupo heterocíclico de 4 a 6 miembros que contiene cuando menos un heteroátomo del anillo seleccionado a partir de nitrogeno, oxígeno y azufre, y R3 es hidrogeno, hidroxilo, alquilo C1-8, alcoxilo C1-8, o tioalquilo C1-8; -CR1R2R3 denota 9H-fluoren-9-ilo, 9,10,-dihidroantracenil-9-ilo, 9-hidroxi-9,10-dihidroantracenil-9-ilo, 9-hidroxi-9H-fluoren-9-ilo, 9H-xanten-9-ilo, 9-hidroxi-9H-xanten-9-ilo, 5H-dibenzo-[a,d]-ciclohepten-5-ilo o 5-hidroxi-5H-dibenzo[a,d]-ciclohepten-5-ilo; y R4 es alquilo C1-8 sustituido en una, dos o tres posiciones por -CO-N(R5)R6, en donde R5 es hidrogeno o alquilo C1-8, y R6 es un grupo heterocíclico de 4 a 6 miembros que contiene cuando menos un heteroátomo del anillo seleccionado a partir de nitrogeno, oxígeno, y azufre; o R1 y R2 son cada uno fenilo insustituido, R3 es hidroxi, y R4 es alquilo C1-8 sustituido en una, do o tres posiciones por -CO-N(R5)R6, en donde R5 es hidrogeno o alquilo C1-4, y R6 es 5-metil-3-isoxazolilo; o R1 y R2 son cada uno fenilo insustituido, R3 es hidroxilo, y R4 es 1-etilo en una, dos, o tres posiciones por -CO-N(R5)R6, en donde R5 es hidrogeno o alquilo C1-4, y R6 es un grupo heterocíclico de 4 a 6 miembros que contiene cuando menos un heteroátomo del anillo seleccionado a partir de nitrogeno, oxígeno, y azufre; con la condicion de que el compuesto de la formula (1) no es (R)-3-(2-hidroxi-2,2-di-tiofen-2-il-acetoxi)-l-(pirazin-2-ilcarbamoil-metil)-l-azonia-biciclo[2.2.2]-octano, bromuro de (R)-3-(2-hidroxi-2,2-di-tiofen-2-il-acetoxi)-l-(isoxazol-3-ilcarbamoil-metil)-l-azonia-biciclo-[2.2.2]octano, o bromuro de (R)-3- (2-hidroxi-2,2-di-tiofen-2-il-acetoxi)-l-(pirimidin-4-ilcarbamoil-metil)-l-azonia-biciclo-[2.2.2]-octano.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0424284.8A GB0424284D0 (en) | 2004-11-02 | 2004-11-02 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054090A1 true AR054090A1 (es) | 2007-06-06 |
Family
ID=33515948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050104547A AR054090A1 (es) | 2004-11-02 | 2005-10-31 | Derivados de quinuclidina como antagonistas del receptor muscarinico m3. composiciones farmaceuticas y proceso de obtencion |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US7723356B2 (es) |
| EP (2) | EP2206499A1 (es) |
| JP (1) | JP4950896B2 (es) |
| KR (1) | KR101252307B1 (es) |
| CN (1) | CN101056634B (es) |
| AR (1) | AR054090A1 (es) |
| AT (1) | ATE481099T1 (es) |
| AU (1) | AU2005300710B2 (es) |
| BR (1) | BRPI0517945A (es) |
| CA (1) | CA2583237C (es) |
| CY (1) | CY1110952T1 (es) |
| DE (1) | DE602005023639D1 (es) |
| DK (1) | DK1811999T3 (es) |
| EC (1) | ECSP077424A (es) |
| ES (1) | ES2353142T3 (es) |
| GB (1) | GB0424284D0 (es) |
| HR (1) | HRP20100693T1 (es) |
| IL (1) | IL182695A0 (es) |
| JO (1) | JO2613B1 (es) |
| MA (1) | MA29080B1 (es) |
| MX (1) | MX2007005189A (es) |
| MY (1) | MY145207A (es) |
| NO (1) | NO20072371L (es) |
| NZ (1) | NZ554302A (es) |
| PE (1) | PE20060609A1 (es) |
| PL (1) | PL1811999T3 (es) |
| PT (1) | PT1811999E (es) |
| RU (1) | RU2399620C2 (es) |
| SI (1) | SI1811999T1 (es) |
| TN (1) | TNSN07164A1 (es) |
| TW (1) | TW200628154A (es) |
| WO (1) | WO2006048225A1 (es) |
| ZA (1) | ZA200702772B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR044134A1 (es) | 2003-05-02 | 2005-08-24 | Novartis Ag | Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas. |
| US7994211B2 (en) | 2005-08-08 | 2011-08-09 | Argenta Discovery Limited | Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses |
| WO2007022030A2 (en) * | 2005-08-11 | 2007-02-22 | University Of Massachusetts | Methods and compositions for the efficient delivery of therapeutic agents to cells and animals |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| TW200825084A (en) * | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| UA97492C2 (ru) * | 2006-11-14 | 2012-02-27 | Астразенека Аб | Хиниклидиновые производные (гетеро) арилциклогептанкарбоксиловой кислоты как антагонисты мускаринового рецептора |
| RU2009120229A (ru) * | 2006-12-19 | 2011-01-27 | Астразенека Аб (Se) | Производные хинуклидинола в качестве антагонистов мускариновых рецепторов |
| WO2009035542A2 (en) | 2007-09-07 | 2009-03-19 | Theravance, Inc. | Guanidine-containing compounds useful as muscarinic receptor antagonists |
| EP2222637A1 (en) | 2007-12-14 | 2010-09-01 | Theravance, Inc. | Amidine-containing compounds useful as muscarinic receptor antagonists |
| PL2231642T3 (pl) | 2008-01-11 | 2014-04-30 | Novartis Ag | Pirymidyny jako inhibitory kinazy |
| EA017627B1 (ru) * | 2008-05-13 | 2013-01-30 | Астразенека Аб | Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора |
| GB0808708D0 (en) * | 2008-05-13 | 2008-06-18 | Astrazeneca Ab | New compounds 274 |
| BRPI0912657A2 (pt) * | 2008-05-13 | 2016-01-26 | Astrazeneca Ab | produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista beta2-adrenorreceptor |
| GB0808707D0 (en) * | 2008-05-13 | 2008-06-18 | Argenta Discovery Ltd | New compounds 275 |
| US20090326004A1 (en) * | 2008-06-03 | 2009-12-31 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| GB0811100D0 (en) * | 2008-06-17 | 2008-07-23 | Astrazeneca Ab | New combination |
| WO2009153536A1 (en) * | 2008-06-17 | 2009-12-23 | Argenta Discovery Limited | 1-aza-bicyclo [2.2.2] octane derivatives useful as muscarinic receptor antagonists |
| US8263623B2 (en) | 2008-07-11 | 2012-09-11 | Pfizer Inc. | Triazol derivatives useful for the treatment of diseases |
| EP2206712A1 (en) * | 2008-12-23 | 2010-07-14 | CHIESI FARMACEUTICI S.p.A. | "Alkaloid aminoester derivatives and medicinal composition thereof" |
| WO2010115937A1 (en) | 2009-04-09 | 2010-10-14 | Novartis Ag | Process for preparing pyrrolidinium salts |
| EP2585457B1 (en) * | 2010-06-22 | 2015-07-22 | Chiesi Farmaceutici S.p.A. | Alkaloid aminoester derivatives and medicinal composition thereof |
| WO2011160920A1 (en) * | 2010-06-22 | 2011-12-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulation comprising an antimuscarinic drug |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| US9102671B2 (en) | 2011-02-25 | 2015-08-11 | Novartis Ag | Compounds and compositions as TRK inhibitors |
| JP2011195593A (ja) * | 2011-06-30 | 2011-10-06 | Astrazeneca Ab | ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体 |
| KR20150095888A (ko) | 2012-12-19 | 2015-08-21 | 노파르티스 아게 | 오토탁신 억제제 |
| EP3134398A1 (en) | 2014-04-24 | 2017-03-01 | Novartis Ag | Autotaxin inhibitors |
| US20170065589A1 (en) * | 2014-05-06 | 2017-03-09 | Anthony G. Visco | Methods of treating or preventing preterm labor |
| CN109851615B (zh) * | 2019-04-22 | 2021-06-08 | 上海旭东海普药业有限公司 | 纯化戊乙奎醚的方法 |
Family Cites Families (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3833592A (en) | 1966-05-31 | 1974-09-03 | Little Inc A | Tropanyl alpha,alpha-diphenyl-alpha-fluoroacetate esters |
| GB1219606A (en) | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
| JPS6235216A (ja) | 1985-08-09 | 1987-02-16 | Noritoshi Nakabachi | 不均質物質層の層厚非破壊測定方法および装置 |
| GB8916480D0 (en) | 1989-07-19 | 1989-09-06 | Glaxo Group Ltd | Chemical process |
| PT100441A (pt) | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
| WO1993018007A1 (en) | 1992-03-13 | 1993-09-16 | Tokyo Tanabe Company Limited | Novel carbostyril derivative |
| WO1993019751A1 (en) | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
| WO1993019750A1 (en) | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compounds useful for treating allergic or inflammatory diseases |
| EP0633776B1 (en) | 1992-04-02 | 2001-05-09 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
| GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
| GB9414193D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
| GB9414208D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
| GB9617730D0 (en) | 1996-08-23 | 1996-10-02 | Pfizer Ltd | Quarternary ammonium compounds |
| GB9622386D0 (en) | 1996-10-28 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| TW528755B (en) | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
| WO1999016766A1 (fr) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Derives de benzodioxole |
| GB9723589D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| GB9723566D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| GB9723590D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| YU44900A (sh) | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola |
| CO4990969A1 (es) | 1998-02-14 | 2000-12-26 | Glaxo Group Ltd | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| GB9813565D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| GB9813540D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| DE69910213T2 (de) | 1998-06-23 | 2004-07-01 | Glaxo Group Ltd., Greenford | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivate |
| GB9813535D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| BR9815931A (pt) | 1998-06-30 | 2001-02-20 | Dow Chemical Co | Polióis poliméricos, um processo para sua produção, e espuma de poliuretanoobtida |
| BR9914526A (pt) | 1998-10-16 | 2001-07-03 | Pfizer | Derivados de adenina |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| US6683115B2 (en) | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
| GB9913932D0 (en) | 1999-06-15 | 1999-08-18 | Pfizer Ltd | Purine derivatives |
| US6322771B1 (en) | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
| ES2165768B1 (es) * | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| PT1212089E (pt) | 1999-08-21 | 2006-08-31 | Altana Pharma Ag | Combinacao sinergica de roflumilast e salmeterol |
| CO5180581A1 (es) | 1999-09-30 | 2002-07-30 | Pfizer Prod Inc | Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia |
| GB9924363D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Central Res | Purine derivatives |
| GB9924361D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Ltd | Purine derivatives |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| GB0003960D0 (en) | 2000-02-18 | 2000-04-12 | Pfizer Ltd | Purine derivatives |
| IL152140A0 (en) | 2000-04-27 | 2003-05-29 | Boehringer Ingelheim Pharma | Novel, slow-acting betamimetics, a method for their production and their use as medicaments |
| TWI227240B (en) | 2000-06-06 | 2005-02-01 | Pfizer | 2-aminocarbonyl-9H-purine derivatives |
| PT1300407E (pt) | 2000-06-27 | 2004-05-31 | S A L V A T Lab Sa | Compostos carbamatos derivados de arilalquilaminas |
| GB0015727D0 (en) | 2000-06-27 | 2000-08-16 | Pfizer Ltd | Purine derivatives |
| GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| DE10038639A1 (de) | 2000-07-28 | 2002-02-21 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| BRPI0113042B8 (pt) | 2000-08-05 | 2021-05-25 | Glaxo Group Ltd | composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato |
| AU2001282874A1 (en) | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| WO2002016356A2 (en) | 2000-08-18 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| WO2002016357A2 (en) | 2000-08-18 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| EP1311505A2 (en) | 2000-08-21 | 2003-05-21 | PHARMACIA & UPJOHN COMPANY | Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands ) |
| WO2002017358A2 (en) | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists) |
| WO2002015662A2 (en) | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists |
| GB0022695D0 (en) | 2000-09-15 | 2000-11-01 | Pfizer Ltd | Purine Derivatives |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| DK1345937T3 (da) | 2000-12-22 | 2006-01-16 | Almirall Prodesfarma Ag | Quinuclidincarbamatderivater og deres anvendelse som M3-antagonister |
| US6476222B2 (en) | 2001-01-05 | 2002-11-05 | Sun Chemical Corporation | Preparation of heat stable pigment violet 23 |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| JP2004526720A (ja) | 2001-03-08 | 2004-09-02 | グラクソ グループ リミテッド | βアドレナリン受容体のアゴニスト |
| EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| ES2296923T3 (es) | 2001-03-22 | 2008-05-01 | Glaxo Group Limited | Derivados formanilidas como agonistas del adrenorreceptor beta2. |
| BR0209271A (pt) | 2001-04-30 | 2004-06-15 | Glaxo Group Ltd | Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto |
| EP1395287A1 (en) | 2001-05-25 | 2004-03-10 | Pfizer Inc. | An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases |
| US20040248867A1 (en) | 2001-06-12 | 2004-12-09 | Keith Biggadike | Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives |
| USRE44874E1 (en) | 2001-09-14 | 2014-04-29 | Glaxo Group Limited | Phenethanolamine derivatives for treatment of respiratory diseases |
| GB0125259D0 (en) | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
| AR037517A1 (es) | 2001-11-05 | 2004-11-17 | Novartis Ag | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria |
| US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| AU2002356759A1 (en) | 2001-12-01 | 2003-06-17 | Glaxo Group Limited | 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents |
| US7452904B2 (en) | 2001-12-20 | 2008-11-18 | Chiesi Farmaceutici S.P.A. | 1-alkyl-1-azoniabicyclo' 2.2.2 octane carbamate derivatives and their use as muscarinic receptor antagonists |
| AU2003202044A1 (en) | 2002-01-15 | 2003-09-09 | Glaxo Group Limited | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents |
| AU2003201693A1 (en) | 2002-01-21 | 2003-09-02 | Glaxo Group Limited | Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents |
| GB0202216D0 (en) | 2002-01-31 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| CN1633296A (zh) | 2002-03-26 | 2005-06-29 | 贝林格尔·英格海姆药物公司 | 糖皮质素模拟物、其制备方法、药物组合物及其用途 |
| JP2005521717A (ja) | 2002-03-26 | 2005-07-21 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用 |
| ATE381336T1 (de) | 2002-04-10 | 2008-01-15 | Univ Virginia | Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten |
| CA2481320A1 (en) | 2002-04-11 | 2003-10-23 | Merck & Co., Inc. | 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| AU2003222841A1 (en) | 2002-04-25 | 2003-11-10 | Glaxo Group Limited | Phenethanolamine derivatives |
| US6747043B2 (en) | 2002-05-28 | 2004-06-08 | Theravance, Inc. | Alkoxy aryl β2 adrenergic receptor agonists |
| US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| DE10224888A1 (de) | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| DE10225574A1 (de) | 2002-06-10 | 2003-12-18 | Merck Patent Gmbh | Aryloxime |
| DE10227269A1 (de) | 2002-06-19 | 2004-01-08 | Merck Patent Gmbh | Thiazolderivate |
| ES2203327B1 (es) | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
| AU2003243870B2 (en) | 2002-06-25 | 2008-11-20 | Merck Frosst Canada Ltd | 8-(biaryl) quinoline PDE4 inhibitors |
| EP1519922A1 (en) | 2002-07-02 | 2005-04-06 | Merck Frosst Canada & Co. | Di-aryl-substituted ethane pyridone pde4 inhibitors |
| EP1521733B1 (en) | 2002-07-08 | 2014-08-20 | Pfizer Products Inc. | Modulators of the glucocorticoid receptor |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| AR040962A1 (es) | 2002-08-09 | 2005-04-27 | Novartis Ag | Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto |
| WO2004018449A1 (en) | 2002-08-10 | 2004-03-04 | Altana Pharma Ag | Piperidine-derivatives as pde4 inhibitors |
| US20060167001A1 (en) | 2002-08-10 | 2006-07-27 | Sterk Jan G | Pyridazinone-derivatives as pde4 inhibitors |
| WO2004018457A1 (en) | 2002-08-10 | 2004-03-04 | Altana Pharma Ag | Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors |
| WO2004018450A1 (en) | 2002-08-10 | 2004-03-04 | Altana Pharma Ag | Piperidine-n-oxide-derivatives |
| RS20050117A (en) | 2002-08-17 | 2007-06-04 | Altana Pharma Ag., | Novel benzonaphthyridines |
| EP1537086A2 (en) | 2002-08-17 | 2005-06-08 | ALTANA Pharma AG | Novel phenanthridines |
| JP2006504678A (ja) | 2002-08-21 | 2006-02-09 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用 |
| ATE353217T1 (de) | 2002-08-29 | 2007-02-15 | Altana Pharma Ag | 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren |
| JP4587294B2 (ja) | 2002-08-29 | 2010-11-24 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐｄｅ４インヒビターとしての２−ヒドロキシ−６−フェニルフェナントリジン |
| EP1539141B1 (en) | 2002-08-29 | 2010-07-14 | Boehringer Ingelheim Pharmaceuticals Inc. | 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| AU2003270783C1 (en) | 2002-09-20 | 2010-05-20 | Merck Sharp & Dohme Corp. | Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
| DE10246374A1 (de) | 2002-10-04 | 2004-04-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| WO2004032921A1 (en) | 2002-10-11 | 2004-04-22 | Pfizer Limited | Indole derivatives as beta-2 agonists |
| EP1440966A1 (en) | 2003-01-10 | 2004-07-28 | Pfizer Limited | Indole derivatives useful for the treatment of diseases |
| ES2291733T3 (es) | 2002-10-22 | 2008-03-01 | Glaxo Group Limited | Compuestos de ariletanolamina medicinales. |
| JP2006506379A (ja) | 2002-10-23 | 2006-02-23 | グレンマーク・ファーマシューティカルズ・リミテッド | 炎症性およびアレルギー性疾患の治療に有用な新規三環式化合物：その調製方法およびそれらを含む医薬組成物 |
| SI1556342T1 (sl) | 2002-10-28 | 2008-08-31 | Glaxo Group Ltd | Fenetanolaminski derivat za zdravljenje respiratornih bolezni |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| GB0225287D0 (en) | 2002-10-30 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| DE10253426B4 (de) | 2002-11-15 | 2005-09-22 | Elbion Ag | Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung |
| DE10253220A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE10253282A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| DE10261874A1 (de) | 2002-12-20 | 2004-07-08 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| JP4606408B2 (ja) | 2003-01-21 | 2011-01-05 | メルク・シャープ・エンド・ドーム・コーポレイション | 選択的グルココルチコイド受容体調節物質としての１７−カルバモイルオキシコルチゾル誘導体 |
| EP1460064A1 (en) | 2003-03-14 | 2004-09-22 | Pfizer Limited | Indole-2-carboxamide derivatives useful as beta-2 agonists |
| US7317102B2 (en) | 2003-04-01 | 2008-01-08 | Theravance, Inc. | Diarylmethyl and related compounds |
| JP4516064B2 (ja) | 2003-04-04 | 2010-08-04 | ノバルティス アーゲー | 気道疾患の処置のためのキノリン−２−オン誘導体 |
| AR044134A1 (es) | 2003-05-02 | 2005-08-24 | Novartis Ag | Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas. |
| US7268147B2 (en) | 2003-05-15 | 2007-09-11 | Pfizer Inc | Compounds useful for the treatment of diseases |
| EP1477167A1 (en) | 2003-05-15 | 2004-11-17 | Pfizer Limited | [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists |
| US7358244B2 (en) | 2003-05-28 | 2008-04-15 | Theravance, Inc. | Azabicycloalkane compounds |
| CA2527334A1 (en) | 2003-06-04 | 2004-12-16 | Pfizer Inc. | 2-amino-pyridine derivatives as beta-2 adrenoreceptor agonists |
| GB0312832D0 (en) | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
| DE10332239B3 (de) | 2003-07-16 | 2005-03-03 | Framatome Anp Gmbh | Zirkoniumlegierung und Bauteile für den Kern von leichtwassergekühlten Kernreaktoren |
| WO2005033121A2 (en) | 2003-10-03 | 2005-04-14 | King Pharmaceuticals Research & Development, Inc. | Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs |
| GB0323701D0 (en) | 2003-10-09 | 2003-11-12 | Glaxo Group Ltd | Formulations |
| GB0324654D0 (en) | 2003-10-22 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| GB0324886D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| GB0329182D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Chemical compounds |
| US7534342B2 (en) | 2003-12-19 | 2009-05-19 | Shell Oil Company | Systems, methods, and catalysts for producing a crude product |
| DE102004001413A1 (de) | 2004-01-09 | 2005-08-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Hydroxymethyl-4-Hydroxy-Phenyl-Derivate zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| TW200531692A (en) | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| ES2239546B1 (es) * | 2004-03-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos esteres de quinuclidina cuaternizados. |
| TWI363759B (en) | 2004-04-27 | 2012-05-11 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| ES2246170B1 (es) | 2004-07-29 | 2007-04-01 | Almirall Prodesfarma, S.A. | Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio. |
-
2004
- 2004-11-02 GB GBGB0424284.8A patent/GB0424284D0/en not_active Ceased
-
2005
- 2005-10-12 JO JOP/2005/0145A patent/JO2613B1/ar active
- 2005-10-24 MY MYPI20054966A patent/MY145207A/en unknown
- 2005-10-31 EP EP10156591A patent/EP2206499A1/en not_active Withdrawn
- 2005-10-31 PE PE2005001274A patent/PE20060609A1/es not_active Application Discontinuation
- 2005-10-31 RU RU2007120454/04A patent/RU2399620C2/ru not_active IP Right Cessation
- 2005-10-31 US US11/577,417 patent/US7723356B2/en not_active Expired - Fee Related
- 2005-10-31 PL PL05798470T patent/PL1811999T3/pl unknown
- 2005-10-31 JP JP2007538352A patent/JP4950896B2/ja not_active Expired - Fee Related
- 2005-10-31 AT AT05798470T patent/ATE481099T1/de active
- 2005-10-31 ES ES05798470T patent/ES2353142T3/es active Active
- 2005-10-31 NZ NZ554302A patent/NZ554302A/en not_active IP Right Cessation
- 2005-10-31 CN CN2005800380673A patent/CN101056634B/zh not_active Expired - Fee Related
- 2005-10-31 EP EP05798470A patent/EP1811999B1/en active Active
- 2005-10-31 MX MX2007005189A patent/MX2007005189A/es active IP Right Grant
- 2005-10-31 DE DE602005023639T patent/DE602005023639D1/de active Active
- 2005-10-31 AU AU2005300710A patent/AU2005300710B2/en not_active Ceased
- 2005-10-31 PT PT05798470T patent/PT1811999E/pt unknown
- 2005-10-31 DK DK05798470.0T patent/DK1811999T3/da active
- 2005-10-31 CA CA2583237A patent/CA2583237C/en not_active Expired - Fee Related
- 2005-10-31 BR BRPI0517945-9A patent/BRPI0517945A/pt not_active IP Right Cessation
- 2005-10-31 WO PCT/EP2005/011662 patent/WO2006048225A1/en active Application Filing
- 2005-10-31 SI SI200531188T patent/SI1811999T1/sl unknown
- 2005-10-31 AR ARP050104547A patent/AR054090A1/es not_active Application Discontinuation
- 2005-10-31 KR KR1020077009938A patent/KR101252307B1/ko not_active IP Right Cessation
- 2005-11-01 TW TW094138292A patent/TW200628154A/zh unknown
-
2007
- 2007-04-03 ZA ZA200702772A patent/ZA200702772B/xx unknown
- 2007-04-19 IL IL182695A patent/IL182695A0/en unknown
- 2007-04-27 EC EC2007007424A patent/ECSP077424A/es unknown
- 2007-04-30 TN TNP2007000164A patent/TNSN07164A1/fr unknown
- 2007-05-08 NO NO20072371A patent/NO20072371L/no not_active Application Discontinuation
- 2007-05-30 MA MA29952A patent/MA29080B1/fr unknown
-
2010
- 2010-03-11 US US12/721,897 patent/US8084463B2/en not_active Expired - Fee Related
- 2010-11-25 CY CY20101101081T patent/CY1110952T1/el unknown
- 2010-12-14 HR HR20100693T patent/HRP20100693T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054090A1 (es) | Derivados de quinuclidina como antagonistas del receptor muscarinico m3. composiciones farmaceuticas y proceso de obtencion | |
| CO5700774A2 (es) | Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1 | |
| AR038235A1 (es) | Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1 | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR079231A1 (es) | Derivados de imidazoquinolina | |
| AR067412A1 (es) | Moduladores de propiedades farmaceuticas de productos terapeuticos | |
| AR032072A1 (es) | Derivados de quinuclidina novedosos y composiciones medicinales que los contienen | |
| AR040047A1 (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6 | |
| AR066492A1 (es) | Derivados de imidazoquinolina, proceso para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de enfermedades virales, bacterianas, alergicas y distintos tipos de canceres. | |
| BRPI0707491B8 (pt) | compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas | |
| AR059905A1 (es) | Pirrolidina-3-ilaminas n-substituidas como antagonistas del receptor histamina-3, composicion farmaceutica y proceso para preparar el compuesto | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| EA201000484A1 (ru) | Тиенопиримидиновые и пиразолопиримидиновые соединения и их применение в качестве ингибиторов киназы mtor и киназы pi3 | |
| HRP20080338T3 (en) | New quaternized quinuclidine esters | |
| ECSP088871A (es) | Derivados de triazolopirazina | |
| AR043015A1 (es) | Compuestos moduladores de amida derivada de quinolina del receptor vanilloide vr1, composiciones farmaceuticas y veterinarias que los contienen y su uso en el tratamiento de enfermedades afectadas por la modulacion de dichos receptores | |
| EA200600892A1 (ru) | Новые хинолиновые производные | |
| AR038000A1 (es) | Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento | |
| AR070936A1 (es) | 1,2,4 -triazoles trisustituidos | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| CO6300861A2 (es) | Compuestos inhibidores de dipeptidil peptidasa iv metodos de preparacion de los mismos y composiciones farmaceuticas que los contienen como agentes activos | |
| AR061015A1 (es) | Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto | |
| AR015528A1 (es) | Compuestos heterociclicos como inhibidores de enzimas rotamasas, composiciones, su uso para la preparacion de medicinas, proceso para su preparacion ycompuestos intermediarios | |
| AR040048A1 (es) | Derivados de 1-(aminoalquil)-3-sulfonilindol e indazol como ligandos de la 5-hidroxitriptamina-6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |